BridgeBio Pharma and Kyowa Kirin Announce Partnership with
- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan - BridgeBio to receive...
Stay updated with breaking news from Nasdaq Bbio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan - BridgeBio to receive...
Blueshift Asset Management LLC purchased a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 16,482 shares of the company’s stock, valued at approximately $435,000. Several other large investors have also recently made changes to […]
BMO Capital Markets assumed coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a research note published on Wednesday morning, MarketBeat reports. The firm issued a market perform rating and a $37.00 price objective on the stock. A number of other brokerages also recently issued reports on BBIO. Citigroup assumed coverage on BridgeBio […]
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1 […]
PALO ALTO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage...